Race intensifies to lead next wave of obesity drugs as trial results loom

BioPharma DiveFDA approves AstraZeneca’s new kind of hypertension drug

BioPharma DiveMerck ADC, licensed from China, hits mark in first big global trial

Boston ScientificBoston Scientific buys $1.5B stake in TAVR developer MiRus - MedTech Dive

Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targets

FierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal

FierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger

BioWorldBiggest gainers and losers for May 11-15, 2026

Endpoints NewsDesign Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China

QiagenQiagen stock (NL0012169213): QIAGEN’s U.S. diagnostics exposure stays in focus - AD HOC NEWS

BioPharma DiveHøeg fired in latest FDA shakeup; 20 people die after taking Amgen drug

Endpoints NewsMerck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule

Endpoints NewsThe Supreme Court won't take up drugmakers' IRA cases